Corbus Pharmaceuticals Holdings Inc
CRBP8.120USD
+0.020+0.25%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
101.78MMarket Cap
LossP/E TTM
More Details of Corbus Pharmaceuticals Holdings Inc Company
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
Corbus Pharmaceuticals Holdings Inc Info
Ticker SymbolCRBP
Company nameCorbus Pharmaceuticals Holdings Inc
IPO dateOct 24, 2014
CEOCohen (Yuval)
Number of employees28
Security typeOrdinary Share
Fiscal year-endOct 24
Address500 River Ridge Drive
CityNORWOOD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02062
Phone16179630103
Websitehttps://www.corbuspharma.com/
Ticker SymbolCRBP
IPO dateOct 24, 2014
CEOCohen (Yuval)
Company Executives of Corbus Pharmaceuticals Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Sean F. Moran, CPA
Mr. Sean F. Moran, CPA
Chief Financial Officer
Chief Financial Officer
15.68K
--
Dr. Yuval Cohen, Ph.D.
Dr. Yuval Cohen, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
14.63K
--
Mr. Alan F. Holmer, J.D.
Mr. Alan F. Holmer, J.D.
Independent Director
Independent Director
7.85K
+157.58%
Dr. Dominic Smethurst
Dr. Dominic Smethurst
Chief Medical Officer
Chief Medical Officer
6.11K
-92.09%
Dr. Yong Ben, M.D., Ph.D.
Dr. Yong Ben, M.D., Ph.D.
Independent Director
Independent Director
4.80K
--
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Independent Chairman of the Board
Independent Chairman of the Board
4.80K
--
Dr. Anne Altmeyer, Ph.D.
Dr. Anne Altmeyer, Ph.D.
Independent Director
Independent Director
3.41K
--
Dr. Ian Hodgson
Dr. Ian Hodgson
Chief Operating Officer
Chief Operating Officer
1.23K
--
Dr. John Kenneth Jenkins, M.D.
Dr. John Kenneth Jenkins, M.D.
Independent Director
Independent Director
--
--
Mr. Winston W. Kung
Mr. Winston W. Kung
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Sean F. Moran, CPA
Mr. Sean F. Moran, CPA
Chief Financial Officer
Chief Financial Officer
15.68K
--
Dr. Yuval Cohen, Ph.D.
Dr. Yuval Cohen, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
14.63K
--
Mr. Alan F. Holmer, J.D.
Mr. Alan F. Holmer, J.D.
Independent Director
Independent Director
7.85K
+157.58%
Dr. Dominic Smethurst
Dr. Dominic Smethurst
Chief Medical Officer
Chief Medical Officer
6.11K
-92.09%
Dr. Yong Ben, M.D., Ph.D.
Dr. Yong Ben, M.D., Ph.D.
Independent Director
Independent Director
4.80K
--
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Independent Chairman of the Board
Independent Chairman of the Board
4.80K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Cormorant Asset Management, LP
13.36%
OrbiMed Advisors, LLC
6.68%
Octagon Capital Advisors LP
6.35%
Citadel Advisors LLC
5.59%
The Vanguard Group, Inc.
3.49%
Other
64.54%
Shareholders
Shareholders
Proportion
Cormorant Asset Management, LP
13.36%
OrbiMed Advisors, LLC
6.68%
Octagon Capital Advisors LP
6.35%
Citadel Advisors LLC
5.59%
The Vanguard Group, Inc.
3.49%
Other
64.54%
Shareholder Types
Shareholders
Proportion
Hedge Fund
32.79%
Investment Advisor
7.70%
Private Equity
6.68%
Investment Advisor/Hedge Fund
6.14%
Venture Capital
2.45%
Research Firm
1.93%
Bank and Trust
1.16%
Individual Investor
0.43%
Other
40.72%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
244
9.91M
80.52%
+983.33K
2025Q3
247
9.76M
113.59%
-275.42K
2025Q2
241
10.04M
128.17%
-1.37M
2025Q1
238
11.57M
122.09%
-3.37M
2024Q4
247
12.14M
125.11%
-689.52K
2024Q3
235
12.83M
99.91%
+494.88K
2024Q2
203
12.32M
76.88%
+2.31M
2024Q1
161
10.21M
42.49%
+5.75M
2023Q4
129
1.15M
32.26%
+195.69K
2023Q3
138
958.46K
32.32%
+8.70K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Cormorant Asset Management, LP
2.38M
19.38%
--
--
Jun 30, 2025
OrbiMed Advisors, LLC
1.17M
9.57%
--
--
Jun 30, 2025
Octagon Capital Advisors LP
1.11M
9.1%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
599.50K
4.89%
-72.56K
-10.80%
Jun 30, 2025
Prosight Capital
579.89K
4.73%
+4.76K
+0.83%
Jun 30, 2025
Exome Asset Management LLC
277.32K
2.26%
-12.37K
-4.27%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
336.42K
2.75%
-454.48K
-57.46%
Jun 30, 2025
Comerica, Inc.
200.00K
1.63%
--
--
Jun 30, 2025
Armistice Capital LLC
192.00K
1.57%
-58.00K
-23.20%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.03%
Avantis US Small Cap Equity ETF
0.01%
Pacer WealthShield ETF
0%
Harbor Health Care ETF
0%
ProShares Hedge Replication ETF
0%
Tema Oncology ETF
0%
Schwab U.S. Broad Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Vanguard US Momentum Factor ETF
0%
Fidelity Enhanced Small Cap ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.03%
Avantis US Small Cap Equity ETF
Proportion0.01%
Pacer WealthShield ETF
Proportion0%
Harbor Health Care ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Tema Oncology ETF
Proportion0%
Schwab U.S. Broad Market ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Vanguard US Momentum Factor ETF
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 13, 2023
Merger
30→1
Feb 13, 2023
Merger
30→1
Feb 13, 2023
Merger
30→1
Feb 13, 2023
Merger
30→1
Date
Type
Ratio
Feb 13, 2023
Merger
30→1
Feb 13, 2023
Merger
30→1
Feb 13, 2023
Merger
30→1
Feb 13, 2023
Merger
30→1
FAQs
Who are the top five shareholders of Corbus Pharmaceuticals Holdings Inc?
The top five shareholders of Corbus Pharmaceuticals Holdings Inc are:
Cormorant Asset Management, LP holds 2.38M shares, accounting for 19.38% of the total shares.
OrbiMed Advisors, LLC holds 1.17M shares, accounting for 9.57% of the total shares.
Octagon Capital Advisors LP holds 1.11M shares, accounting for 9.10% of the total shares.
The Vanguard Group, Inc. holds 599.50K shares, accounting for 4.89% of the total shares.
Prosight Capital holds 579.89K shares, accounting for 4.73% of the total shares.
Cormorant Asset Management, LP holds 2.38M shares, accounting for 19.38% of the total shares.
OrbiMed Advisors, LLC holds 1.17M shares, accounting for 9.57% of the total shares.
Octagon Capital Advisors LP holds 1.11M shares, accounting for 9.10% of the total shares.
The Vanguard Group, Inc. holds 599.50K shares, accounting for 4.89% of the total shares.
Prosight Capital holds 579.89K shares, accounting for 4.73% of the total shares.
What are the top three shareholder types of Corbus Pharmaceuticals Holdings Inc?
The top three shareholder types of Corbus Pharmaceuticals Holdings Inc are:
Cormorant Asset Management, LP
OrbiMed Advisors, LLC
Octagon Capital Advisors LP
Cormorant Asset Management, LP
OrbiMed Advisors, LLC
Octagon Capital Advisors LP
How many institutions hold shares of Corbus Pharmaceuticals Holdings Inc (CRBP)?
As of 2025Q4, 244 institutions hold shares of Corbus Pharmaceuticals Holdings Inc, with a combined market value of approximately 9.91M, accounting for 80.52% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -33.07%.
What is the biggest source of revenue for Corbus Pharmaceuticals Holdings Inc?
In --, the -- business generated the highest revenue for Corbus Pharmaceuticals Holdings Inc, amounting to -- and accounting for --% of total revenue.
